logo
logo

Pax Medica, Inc. announced it raised $1.15 Million in an initial filing from an offering of $3.7 Million

May 10, 2022about 3 years ago

Amount Raised

$1.15 Million

Round Type

seed

TarrytownBiotechnology

Company Information

Company

PaxMedica

Location

303 SOUTH BROADWAY, SUITE 125

Tarrytown, New York, United States

About

PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19.

Related People